Schedule For Drug Fee Estimates Slips As IRS Revises Guidance
Executive Summary
The Internal Revenue Service has pushed back some of the implementation deadlines for the new market-share based fees on drug manufacturers by a couple of weeks to accommodate issues raised in response to its November guidance.
You may also be interested in...
Market-Based Drug Fees: IRS Will Release 2011 Estimates In May, Guidance Says
The IRS guidance proposes a method for calculating the fees and sets out a timetable for the process in 2011, the program's first year. The guidance also describes what corporate entities are liable for the fees and what branded drugs are covered.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.